Key Highlights
- Second-quarter revenue was $76.4 million versus $105.6 million a year earlier.
- The loss was $0.28 per share, with a net loss of about $3.1 million.
- Management is targeting profitability in the fourth quarter of 2026.
- Nicholas Johnson became CEO on June 1, 2026, succeeding Dan Chard.
Medifast, Inc. (NYSE:MED) enters the week with a small-cap valuation of roughly $121 million and a turnaround story that investors may be monitoring closely. The next quarterly report, estimated for around November 2, 2026, could be the key near-term event for assessing whether management's recovery targets are on track.
Latest Company Context
Medifast reported second-quarter 2026 results on August 3, 2026. Revenue was $76.4 million, compared with $105.6 million a year earlier, a substantial year-over-year decline. The company posted a loss of $0.28 per share, versus a loss of $0.22 a year earlier, with a net loss cited at about $3.1 million. Management pointed to early signs of a turnaround and has said it is targeting profitability in the fourth quarter of 2026. Leadership has also changed: Nicholas Johnson became chief executive officer effective June 1, 2026, succeeding Dan Chard. Product and brand initiatives include the July 2026 launch of the Trilivy metabolic health system and the late-August launch of the Medifast Metabolic Health Institute.
Key Business Drivers
Guidance is the central driver. For the third quarter of 2026, management guided to revenue of $60 million to $80 million and a loss per share between $0.65 and $0.15. For the full year, revenue guidance is $270 million to $300 million, and the EPS outlook was raised to a range between a loss of $1.75 and a profit of $0.25, from a previous range of a loss of $2.75 to a loss of $1.55. These figures are management guidance, not guarantees, and the wide ranges indicate meaningful uncertainty. The company's positioning around metabolic health could potentially broaden its addressable market, but it also operates in a competitive weight-management category. No dividend is listed.
What Investors Should Watch
Investors may watch the third-quarter report, estimated for early November, to see where results land within the $60 million to $80 million revenue guidance range and whether the loss narrows toward the better end of the EPS range. Commentary on customer acquisition, coach and channel trends, and the commercial traction of the Trilivy system could be informative. The fourth-quarter profitability target is a specific, testable milestone: any change to the full-year range, up or down, may influence sentiment. Cost controls under the new chief executive, and any further strategic announcements from the Metabolic Health Institute, are other items that may merit attention. Share-price volatility may remain elevated given the small market capitalisation.
A Turnaround Story With a Fourth-Quarter Profitability Target
Medifast pairs a steep revenue decline with early turnaround signs, a new CEO and a fourth-quarter profitability target. The estimated November 2 report is the first check on those targets.



_11_19_2026_18_10_40_422713.jpg)


Please wait processing your request...